Sam-A Pharm삼아제약
009300 · KOSDAQ · ₩009300 · 삼아제약
₩13,670▼ ₩30 (0.22%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩78B | ₩96B | ₩97B | ₩82B | ₩55B |
| Cost of sales | ₩31B | ₩35B | ₩36B | ₩32B | ₩22B |
| Gross profit | ₩46B | ₩61B | ₩62B | ₩50B | ₩33B |
| Operating income | ₩11B | ₩24B | ₩24B | ₩18B | ₩6B |
| Net income | ₩13B | ₩22B | ₩21B | ₩12B | ₩3.4B |
| Net income to shareholders | ₩13B | ₩22B | ₩21B | ₩12B | ₩3.4B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩247B | ₩249B | ₩231B | ₩203B | ₩189B |
| Current assets | ₩136B | ₩113B | ₩118B | ₩117B | ₩82B |
| Cash and equivalents | ₩6.6B | ₩9.6B | ₩9B | ₩9.2B | ₩8B |
| Total liabilities | ₩19B | ₩29B | ₩31B | ₩23B | ₩17B |
| Current liabilities | ₩14B | ₩21B | ₩21B | ₩22B | ₩15B |
| Borrowings | ₩2.3B | ₩6.8B | ₩4.2B | ₩0 | ₩0 |
| Total equity | ₩228B | ₩220B | ₩200B | ₩181B | ₩172B |
| Shareholders' equity | ₩228B | ₩220B | ₩200B | ₩181B | ₩172B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩11B | ₩25B | ₩21B | ₩20B | ₩13B |
| Capital spending | ₩1.4B | ₩6.5B | ₩3.8B | ₩239M | ₩275M |
| Free cash flow | ₩9.4B | ₩19B | ₩17B | ₩19B | ₩13B |
| Dividends paid | ₩4.9B | ₩4.6B | ₩2.4B | ₩1.5B | ₩1.8B |
Consolidated where available. Amounts in won.
Also known as: Sam-A Pharm / 삼아제약 / 009300 / KRX:009300
Source: KRX statistical information